Meeting
2022 ASCO Annual Meeting
Comparison of simulated outcomes between stool- and blood-based colorectal cancer screening tests.
Authors
A. Fendrick
University of Michigan, Ann Arbor, MI
A. Fendrick , Vahab Vahdat , Jing Voon Chen , David A. Lieberman , Jordan J. Karlitz , Paul J. Limburg , A. Burak Ozbay , John B. Kisiel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Cancer Prevention
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 10529)
DOI
10.1200/JCO.2022.40.16_suppl.10529
Abstract #
10529
Poster Bd #
406
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Estimated life-years gained and resultant cost savings from follow-up colonoscopy after a positive multi-target stool DNA (mt-sDNA) test for colorectal cancer screening in commercially insured and Medicare populations.
First Author: A. Mark Fendrick
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Clinical performance of a multimodal screening blood test for advanced adenomas and CRC in an average-risk cohort of 1,038 participants.
First Author: Shai Friedland
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Prevention of colorectal cancer through multiomics blood testing: The PREEMPT CRC study.
First Author: Girish Putcha
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Preferences for colorectal cancer screening of physicians and individuals at average risk in the United States: A discrete choice experiment.
First Author: Sebastian Heidenreich